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OBJECTIVE—Cannabinoid type 1 (CB1) receptor blockade
decreases body weight and adiposity in obese subjects; however,
the underlying mechanism is not yet fully understood. Nitric
oxide (NO) produced by endothelial NO synthase (eNOS) in-
duces mitochondrial biogenesis and function in adipocytes. This
study was undertaken to test whether CB1 receptor blockade
increases the espression of eNOS and mitochondrial biogenesis
in white adipocytes.
RESEARCH DESIGN AND METHODS—We examined the
effects on eNOS and mitochondrial biogenesis of selective phar-
macological blockade of CB1 receptors by SR141716 (rimon-
abant) in mouse primary white adipocytes. We also examined
eNOS expression and mitochondrial biogenesis in white adipose
tissue (WAT) and isolated mature white adipocytes of CB1
receptor–deﬁcient (CB1
/) and chronically SR141716-treated
mice on either a standard or high-fat diet.
RESULTS—SR141716 treatment increased eNOS expression in
cultured white adipocytes. Moreover, SR141716 increased mito-
chondrial DNA amount, mRNA levels of genes involved in
mitochondrial biogenesis, and mitochondrial mass and function
through eNOS induction, as demonstrated by reversal of
SR141716 effects by small interfering RNA–mediated decrease in
eNOS. While high-fat diet–fed wild-type mice showed reduced
eNOS expression and mitochondrial biogenesis in WAT and
isolated mature white adipocytes, genetic CB1 receptor deletion
or chronic treatment with SR141716 restored these parameters to
the levels observed in wild-type mice on the standard diet, an
effect linked to the prevention of adiposity and body weight
increase.
CONCLUSIONS—CB1 receptor blockade increases mitochon-
drial biogenesis in white adipocytes by inducing the expression
of eNOS. This is linked to the prevention of high-fat diet–induced
fat accumulation, without concomitant changes in food intake.
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A
dipose tissue is not merely an energy store but
rather an endocrine organ playing an important
role in fuel metabolism (1,2). Recent studies
have demonstrated that mitochondrial biogen-
esis increases during adipocyte differentiation (3), and this
is presumably due at least in part to the presence of the
endothelial nitric oxide (NO) synthase (eNOS). In fact,
eNOS protein is not expressed in either undifferentiated
3T3-L1 cells or preadipocytes, whereas its expression
markedly increases with adipocyte differentiation (4). It is
noteworthy that NO increases mitochondrial biogenesis in
white adipocytes via cyclic guanosine monophosphate
(cGMP)-dependent pathways, including peroxisome pro-
liferator–activated receptor  coactivator-1 (PGC-1)
gene expression (5,6). Consistently, mitochondrial biogen-
esis is reduced in fat of eNOS-null mutant mice (eNOS
/),
with decreased energy expenditure and increased body
weight (5,6). This suggests that the eNOS-dependent mi-
tochondrial biogenesis is relevant to adipocyte maturation
and fuel metabolism.
Cannabinoid type 1 (CB1) receptors participate in the
physiological modulation of many central and peripheral
functions related to the control of energy metabolism (7).
They are the most abundant G protein–coupled receptors
expressed in the brain, where CB1 receptor activation
promotes feeding and modulates the rewarding properties
of food (7–9). CB1 receptors also control metabolic func-
tions by acting on peripheral organs, including white
adipose tissue (WAT) (7–9). Notably, in adipocytes, CB1
receptor expression increases with cell differentiation
(10,11). Moreover, CB1 receptor–deﬁcient mice (CB1
/)
are lean (12) and resistant to a high-fat diet (13). Similarly,
the selective CB1 receptor antagonist SR141716 (rimon-
abant) persistently reduces body weight during the treat-
ment of obese animals, although food intake renormalizes
after an initial 1- to 2-week weight reduction (14,15),
suggesting that CB1 receptor blockade stimulates fat
metabolism, leading to a decreased fat content.
We now demonstrate a prominent role for the CB1
receptors to modulate eNOS gene expression and mito-
chondrial biogenesis in white adipocytes. Collectively,
these data suggest that targeting the endocannabinoid
system improves mitochondrial function, implying a novel,
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drug rimonabant.
RESEARCH DESIGN AND METHODS
Cell culture. White fat precursor cells were enzymatically isolated from
epididymal WAT of wild-type C57BL/6J mice and cultured as described (16).
SR141716 [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methylpyrazole-3-carboxamide, hydrochloride, contract no. N01-MH-32005
WA 08928.019, National Institute of Mental Health no. S-705, Chemical
Synthesis and Drug Supply Program, National Institute of Mental Health; RTI)]
stock solutions (50 mmol/l in DMSO) were diluted in the culture medium to
the required ﬁnal concentrations containing up to 0.02% DMSO. At days 3–4
from seeding, cells were exposed to the culture medium containing SR141716
(0.1–10 mol/l) for 72 h or different periods of time when speciﬁed. The
medium was discarded, the wells were washed twice with 2 ml ice-cold PBS
(Sigma-Aldrich), and the cells were harvested as reported below for the
different assays.
eNOS small interfering RNA. White adipocytes were transfected at days
3–4 after seeding with 100 nmol/l eNOS small interfering RNA (siRNA)
SMARTpool (Dharmacon, Lafayette, CO) or siCONTROL nontargeting siRNA
using Dharmafect 3 transfection reagent. Cells were treated for 72 h with 1
mol/l SR141716, and RNA and protein were harvested. Efﬁcacy of transfec-
tion was determined using siGLO-RISC–free nontargeting siRNA and estima-
tion of siRNA uptake by ﬂuorescence detection (absorbance/emission 557/570
nm).
Animals and treatments. Animals were treated according to protocols
approved by Milan and Bologna University institutional animal care and use
committee. Eight-week-old male CB1
/ mice (17) and their wild-type litter-
mates (n  10 per group) were fed either a standard mouse diet (8% kcal fat,
19% kcal protein, and 73% kcal carbohydrate) or a high-fat diet (D12492, 60%
kcal fat, 20% kcal protein, and 20% kcal carbohydrate; Research Diets, New
Brunswick, NJ) for 12 weeks. Moreover, 4-week-old male C57BL/6J mice
(Harlan Nossan) were fed either a standard diet or high-fat diet for 6 weeks
before treatments. While fed on the standard or high-fat diet, these mice (n 
10 per group) were further treated with either vehicle or SR141716 (at 10
mg/kg orally in distilled water with 0.1% Tween 80) for 11 weeks. Body weight
and food intake were recorded weekly. Adiposity (wet weight of visceral and
subcutaneous fat), cumulative food intake (for the time of the experiment),
and feed efﬁciency were measured (5). On the day of the experiments, animals
were killed by cervical dislocation and epididymal WAT was immediately
isolated, frozen in liquid nitrogen, and stored at 80°C before processing for
mRNA, protein, and mtDNA analysis or citrate synthase and AMP-activated
protein kinase (AMPK) activity.
Isolation of mouse mature adipocytes. Wild-type and CB1
/ mice were
fed a standard or high-fat diet (n  6 per group), and wild-type mice either on
standard or high-fat diet were treated with either vehicle or SR141716 (n  6
per group) as described above. Mice were killed and epididymal WAT excised.
Fat pads from two mice were pooled, and mature adipocytes were acutely
isolated in Hank’s balanced salt solution containing 4% BSA and 1.5 mg/ml
collagenase (Calbiochem) as described (18).
RNA analysis. RNA was isolated from tissue or cells using the RNeasy Lipid
Tissue Mini Kit (Qiagen). cDNA was synthesized using iScript cDNA Synthesis
Kit (Bio-Rad Laboratories). Primers were designed using Beacon Designer 2.6
software from Premier Biosoft International. Triplicate PCR were carried out
with the intercalating dye SybrGreen as previously described (5,16). PCR
cycles were programmed on an iCycler iQ Real-Time PCR detection system
(Bio-Rad Laboratories). The cycle number at which the various transcripts
were detectable (threshold cycle [CT]) was compared with that of -actin,
referred to as CT. The gene relative level was expressed as 2
(CT), in which
CT equals CT of either the knockout or drug-treated mice (or treated
cells) minus CT of the control mice (or untreated cells).
Immunoblot analysis. Protein extracts were obtained by harvesting cultured
adipocytes in M-PER Mammalian Protein Extraction Reagent or homogenizing
WAT tissue in T-PER Tissue Protein Extraction Reagent (both from Pierce), as
indicated by the manufacturer, in the presence of 1 mmol/l NaVO4, 10 mmol/l
NaF, and a cocktail of protease inhibitors (Sigma-Aldrich). Protein content
was determined by the bicinchoninic acid protein assay (Pierce), and 50 go f
proteins were run on SDS-PAGE under reducing conditions. The separated
proteins were then electrophoretically transferred to a nitrocellulose mem-
brane (Pierce). Proteins of interest were revealed with speciﬁc antibodies:
anti-eNOS (Transduction Labs), anti–cytochrome c oxidase (COX IV) (Molec-
ular Probes), anti–cytochrome c (BD Bioscience), each one at 1:500 dilution;
anti–phospho-AMPK (Thr172) and anti-AMPK (both at 1:1,000 dilution; Cell
Signaling Technology); and anti–-actin (1:10,000; Sigma-Aldrich). The immu-
nostaining was detected using horseradish peroxidase–conjugated anti-rabbit
or anti-mouse immunoglobulin for1ha troom temperature. After the
visualization of phospho-AMPK, ﬁlters were stripped with the Re-Blot
Western blot recycling kit (Chemicon International) and further used for the
visualization of total AMPK. Bands were revealed by the SuperSignal
Substrate (Pierce) and quantitated by densitometry using a Quick Image
densitometer (Canberra Packard) and a Phoretix 1D, version 3.0, software
image analyser.
Fluorescence-activated cell sorting analysis. White adipocytes were
treated or not with 1 mol/l SR141716 for 72 h. Cells (1 	 10
6 per sample)
were harvested by trypsinization, ﬁxed with 4% paraformadehyde in PBS for
10 min, and incubated1ha troom temperature in a permeabilization buffer
containing 1% BSA, 0.1% saponin, and either anti–COX IV or anti–cytochrome
c antibody. After incubation with labeled secondary antibody, the ﬂuores-
cence was analyzed by ﬂow cytometry (FACScan; Becton Dickinson, Sunny-
vale, CA) and Cell Quest software (Becton Dickinson). Data are expressed as
relative ﬂuorescence intensity of the mean ﬂuorescent signal versus unstained
samples.
Mitochondrial DNA. Mitochondria were isolated from tissue and cells (19).
The mitochondrial DNA (mtDNA) was extracted and analyzed as described
(5,16). Brieﬂy, an aliquot of mtDNA was loaded on ethidium bromide–stained
agarose gel (1.2%) and quantiﬁed using the QuickImage densitometer (Pack-
ard). To determine mtDNA levels, the signal intensities were normalized to
cell numbers in experiments on cultured cells or to protein content in
experiments using tissues from wild-type and knockout mice. Alternatively,
mtDNA copy number was measured by means of quantitative PCR from the
cytochrome C oxidase II mtDNA gene compared with the uncoupled protein-2
nuclear gene in WAT of CB1
/ and wild-type mice as described (20).
Oxygen consumption. White adipocytes were harvested by trypsinization,
centrifuged at 500g for 5 min at 4°C, and resuspended in Hank’s balanced salt
solution. Cell samples (4 	 10
6/ml) were analyzed at 37°C in a gas-tight vessel
equipped with a Clark-type oxygen electrode (Rank Brothers) connected to a
chart recorder. Cellular oxygen consumption was measured as described
(5,16). The oxygen electrode was calibrated, assuming the concentration of
oxygen in the incubation medium at 37°C to be 200 mol/l. Protein content in
both cell and tissue samples was determined by the bicinchoninic acid protein
assay (Pierce).
ATP levels. The whole amount of ATP in cells was measured by using the
ATP determination kit from Molecular Probes. Cells were harvested by
trypsinization and centrifuged at 500g for 5 min at 4°C. ATP was extracted by
incubating cell pellets with 1% trichloroacetic acid per 4 mmol/l EDTA
solution for 10 min on ice. Cell extracts were centrifuged at 12,000g for 10 min
at 4°C and used for ATP determination as indicated by the manufacturer.
Mitochondrial mass. White adipocytes seeded onto glass coverslips were
incubated with medium containing 200 nmol/l Mitotracker red 580 (Invitro-
gen). After incubation for 30 min at 37°C, coverslips were rinsed two times
with medium and two times with PBS and ﬁxed at room temperature for 10
min in 4% paraformaldehyde in PBS. Coverslips were mounted onto glass
slides and were then observed with a Bio-Rad confocal microscope MRC1024.
Citrate synthase activity. The activity was measured spectrophotometri-
cally at 412 nm at 30°C in either tissue or whole-cell extracts (21). Tissue or
cell homogenates were added to buffer containing 0.1 mmol/l 5,5-dithio-bis-
(2-nitrobenzoic) acid, 0.5 mmol/l oxaloacetate, 50 mol/l EDTA, 0.31 mmol/l
acetyl CoA, 5 mmol/l triethanolamine hydrochloride, and 0.1 mol/l Tris-HCl,
pH 8.1. Citrate synthase activity was expressed as nanomoles citrate produced
per minute per milligram of protein.
AMPK assay. Adipocytes were scraped in ice-cold lysis buffer (22) in the
presence of 1 mmol/l NaVO4, 10 mmol/l NaF, and protease inhibitors (Sigma-
Aldrich). Epididymal fat pads from wild-type or CB1
/ mice were homoge-
nized in ice-cold lysis buffer. AMPK activity was determined on protein
samples immunoprecipitated with anti-AMPK (Cell Signaling Technology) as
described (22). The immunocomplexes were collected and washed with
AMPK reaction buffer (22). AMPK immunoprecipitates were incubated with 20
l of AMPK reaction buffer, 5 l of SAMS substrate peptide (1 mmol/l), and 2
Ci of [-
32P]ATP (MP Biomedicals) for 30 min at 37°C. At the end of the
incubation, an aliquot was removed and spotted onto Whatman P81 paper.
The P81 paper was washed three times with 0.75% (vol/vol) phosphoric acid
and once with acetone, and radioactivity was determined by scintillation
counting.
Statistical methods. Raw data from each experiment were analyzed using
either an ANOVA with Newman-Keuls’ multiple comparison post hoc test or t
test.
RESULTS
CB1 receptor antagonist increases eNOS expression
and mitochondrial biogenesis in white adipocytes.
L. TEDESCO AND ASSOCIATES
DIABETES, VOL. 57, AUGUST 2008 2029CB1 receptor antagonist SR141716 affects eNOS expres-
sion in mouse white adipocytes in culture. In fact, the drug
signiﬁcantly increased eNOS mRNA (Fig. 1A) and protein
levels (Fig. 1B) in a dose-dependent manner (0.1–10 mol/l
for 72 h).
The effect of SR141716 was further tested on several
markers of mitochondrial biogenesis. The amount of
mtDNA (a marker of mitochondrial content) and the
mRNA levels of PGC-1, nuclear respiratory factor-1
(NRF-1), and mtDNA transcription factor A (Tfam) (three
master regulators of mitochondrial biogenesis) (23,24)
were higher in 1 mol/l SR141716-treated than in vehicle-
treated cells (Fig. 2A). Protein levels of COX IV and
cytochrome c (two mitochondrial proteins involved in
oxidative phosphorylation) were also increased by
SR141716 treatment as assessed either by immunoblot
(Fig. 2B) or by ﬂow cytometry (mean ﬂuorescence inten-
sity 
 SE of SR141716- vs. vehicle-treated cells: 20.1 
 3.4
vs. 9.6 
 2.3 for COX IV and 15.6 
 3.2 vs. 9.9 
 1.9 for
cytochrome c; n  3 experiments; P  0.001). Both activity
of citrate synthase and oxygen consumption were mark-
edly increased by SR141716 treatment (Fig. 2C and D).
Consistently, the ATP levels in the SR141716-treated cells
were signiﬁcantly higher than those in the vehicle-treated
cells (1.73 
 0.19 vs. 1.34 
 0.16; n  3 experiments, P 
0.05). Finally, white adipocytes treated with SR141716
showed a signiﬁcant increase of Mitotracker red signal,
indicating the increase of mitochondrial mass compared
with vehicle-treated cells (Fig. 2E). Altogether, these ﬁnd-
ings demonstrate that pharmacological blockade of the
CB1 receptor increases eNOS expression and mitochon-
drial biogenesis and function in white adipocytes.
SR141716 effects on mitochondrial biogenesis are
eNOS dependent. Coregulation of eNOS expression and
mitochondrial biogenesis in the SR141716-treated adipo-
cytes suggests that these processes might be mechanisti-
cally linked. To assess whether eNOS expression is
relevant in the drug-induced mitochondrial biogenesis,
white adipocytes were transfected with siRNA against
eNOS or a scrambled RNA sequence. siRNA against eNOS
reduced basal eNOS mRNA and protein levels by 82 and
85%, respectively, in WAT cells (Fig. 1C and D), with a
moderate, but statistically signiﬁcant, decrease of all mea-
sured parameters of mitochondrial biogenesis in vehicle-
treated cells (Fig. 2A–E). Importantly, however, siRNA
against eNOS strongly decreased mitochondrial biogenesis
induced by 1 mol/l SR141716 treatment, indicating that
the effect of SR141716 depends, at least in part, on the
presence of eNOS (Fig. 2A–E).
Mitochondrial biogenesis is increased in WAT of
CB1
/ mice. To assess whether the CB1 receptor block-
ade increases mitochondrial biogenesis in WAT in vivo, we
examined the eNOS expression and markers of mitochon-
drial biogenesis in epididymal fat pads derived from
8-week-old male CB1
/ mice and their wild-type litter-
mates either on a standard or high-fat diet for 12 weeks. As
expected (16), a high-fat diet reduced eNOS expression
and mitochondrial biogenesis in wild-type mice (Fig. 3A–
D). eNOS mRNA levels in WAT of CB1
/ mice were
signiﬁcantly higher than those of wild-type mice on both
the standard and high-fat diets (Fig. 3A). Furthermore,
CB1
/ mice displayed increased mRNA levels of PGC-1
and Tfam (Fig. 3A), COX IV, and cytochrome c (Fig. 3C);
increased mtDNA amounts (Fig. 3B); and increased citrate
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FIG. 1. The CB1 receptor antagonist SR141716 dose-dependently upregulates eNOS expression in cultured white adipocytes. A and B: eNOS
mRNA and protein, analyzed by quantitative RT-PCR and immunoblotting, respectively, in vehicle-treated cells (0.02% DMSO) (Veh) or after
exposure to different doses of SR141716 for 3 days. The cycle number at which the transcript was detectable was compared with that of -actin
and expressed as relative expression versus values in vehicle-treated cells taken as 1.0 (n  5 experiments) (*P < 0.05 vs. vehicle). eNOS protein
was detected by immunoblot analysis (in B, one experiment representative of ﬁve reproducible ones). The numbers below the blots show the
relative values from the densitometric analysis, relative to -actin levels, when control (vehicle) measurement is given a value of 1.0. C and D:
eNOS expression in white adipocytes transfected with either 100 nmol/l scrambled control siRNA or eNOS siRNA and harvested 48 h later. eNOS
mRNA and protein levels were measured by means of quantitative RT-PCR and immunoblotting (n  3 experiments) (***P < 0.01 vs. transfection
reagent-treated cells). All data represent means  SE.
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2030 DIABETES, VOL. 57, AUGUST 2008synthase activity (Fig. 3D) compared with wild-type litter-
mates. These increments were evident in animals either on
standard or high-fat diets. To conﬁrm that the mitochon-
drial biogenesis induced by CB1 gene deletion occurs in
white adipocytes in vivo, mature white adipocytes were
isolated from the epididymal fat pad of CB1
/ and
wild-type littermates after standard or high-fat diets. Al-
though we do not rule out that other cell types present in
whole WAT (i.e., endothelial cells, macrophages, or oth-
ers) may be involved, we found that CB1 gene deletion
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chondrial biogenesis through
eNOS expression in cultured
white adipocytes. A: PGC-1,
NRF-1, and Tfam mRNA levels
were analyzed by means of quan-
titative RT-PCR with gene-spe-
ciﬁc oligonucleotide probes in
white adipocytes treated either
with vehicle (0.002% DMSO)
(Veh) or 1 mol/l SR141716 (SR)
or 100 nmol/l eNOS siRNA
(siRNA) either alone or com-
bined. The cycle number at which
the various transcripts were de-
tectable was compared with that
of -actin and expressed as rela-
tive expression versus values in
vehicle-treated cells taken as 1.0
(n  5 experiments). *P < 0.05
and ***P < 0.01 vs. vehicle-
treated cells; †P < 0.05 vs.
SR141716-treated cells. Inset:
mtDNA (one experiment repre-
sentative of ﬁve gels). The num-
bers show the relative amounts
from the densitometric analysis
when vehicle treatment measure-
ments are given a value of 1.0;
(M, DNA marker). B: COX IV and
cytochrome c proteins were de-
tected by immunoblot analysis
(one experiment representative
of ﬁve reproducible ones) in
white adipocytes. The numbers
below the blots show the relative
values from the densitometric
analysis, referred to -actin lev-
els, when vehicle-treated cell
measurement is given a value of
1.0. Citrate synthase activity (C)
and oxygen consumption by
white adipocytes (D). The values
were normalized to the cell pro-
tein content (n  3 experi-
ments). *P < 0.05 vs. vehicle-
treated cells and †P < 0.05 vs.
SR141716-treated cells. All data
represent means  SE. E: Mito-
chondrial mass in white fat cells
visualized as mitotracker red sig-
nal by confocal microscopy. Im-
ages were acquired by using a
40 objective lens. (Please see
http://dx.doi.org/10.2337/db07-
1623 for a high-quality digital
representation of this ﬁgure.)
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and function in white adipocytes (online appendix Fig. 1
[available at http://dx.doi.org/10.2337/db07-1623]).
As previously described (12), CB1
/ mice on the stan-
dard diet had a lower body weight and adiposity (online
appendix Fig. 2A) than wild-type controls, having showed
a signiﬁcantly reduced body weight compared with wild-
type mice throughout the whole period of observation
(data not shown). Most importantly, CB1
/ mice main-
tained a leaner phenotype under the high-fat diet as
evidenced by lower body weight and adiposity (online
appendix Fig. 2A and B) (13). Cumulative food intake was
comparable between the two groups of mice on standard
or high-fat diet (online appendix Fig. 2C), although CB1
/
mice showed a smaller feed efﬁciency (weight gain/food
intake, an indirect measurement of increased energy ex-
penditure) than their wild-type littermates (online appen-
dix Fig. 2D).
Defective mitochondrial biogenesis is restored in
WAT of high-fat diet–fed SR141716-treated mice. CB1
receptor effects on mitochondrial biogenesis were further
conﬁrmed in vivo by a long-term treatment with the CB1
receptor antagonist. Four-week-old male mice were put on
either standard or high-fat diet. Starting at week 10,
standard diet– and high-fat diet–fed mice were treated
either with SR141716 (10 mg  kg
1 day
1 orally) or vehicle
for 11 weeks (13–15). Consistent with the data from
CB1
/ mice, eNOS mRNA and protein levels and mito-
chondrial biogenesis were signiﬁcantly higher in WAT of
the SR141716-treated high-fat diet–fed mice than in those
of vehicle-treated high-fat diet–fed mice, although as ex-
pected (16), they were lower in the vehicle-treated high-fat
diet–fed mice than in the vehicle-treated standard diet–fed
mice (Fig. 4). These results suggest that SR141716 treat-
ment amends the high-fat diet–induced impairment of the
NO generating system, restoring the mitochondrial func-
tion at levels observed in wild-type mice on a standard
diet. Treatment with SR141716 induced only a slight, but
not statistically signiﬁcant, increase of eNOS expression
and mitochondrial biogenesis in mice on the standard diet
(Fig. 4). Superimposable results were obtained in isolated
mature white adipocytes from SR141716-treated mice (on-
line appendix Fig. 3).
Interestingly, the mean body weight and adiposity of the
SR141716-treated mice were markedly lower compared
with that of vehicle-treated mice on the high-fat diet
(online appendix Fig. 4A and B). Cumulative food intake
was comparable between the drug- and vehicle-treated
animals on a high-fat diet (online appendix Fig. 4C),
whereas SR141716-treated mice showed a reduced feed
efﬁciency compared with their vehicle-treated high-fat
diet–fed controls (online appendix Fig. 4D). Only slight,
but not statistically signiﬁcant, decreases in body weight
and adiposity were seen in the SR141716-treated mice on a
standard diet (online appendix Fig. 4A and B).
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lation and activity. The AMPK cascade has been de-
scribed to activate eNOS and NO production (25). Thus,
AMPK might be involved in the effect of CB1 receptor
blockade on eNOS-mediated mitochondrial biogenesis. In
fact, treatment of cultured white adipocytes with 1 mol/l
SR141716 induced a rapid and persistent AMPK phosphor-
ylation (Fig. 5A) and signiﬁcantly increased AMPK activity
(Fig. 5B). Moreover, in line with previous reports (26), we
found that AMPK activity was lower in the WAT of
wild-type mice fed a high-fat diet compared with those fed
a standard diet. Noticeably, while CB1 receptor deletion
did not affect AMPK phosphorylation or activity in WAT of
standard diet–fed mice (Fig. 5C and D), both AMPK
phosphorylation (Fig. 5C) and activity (Fig. 5D) were
normalized in the WAT of high-fat diet–fed CB1
/ mice,
up to the levels measured in wild-type standard diet–fed
mice.
Taken together, these ﬁndings demonstrate that the CB1
receptor blockade in vivo concomitantly activates AMPK
cascade and upregulates eNOS expression and mitochon-
drial biogenesis, which are impaired by a high-fat diet in
WAT, and these processes may be involved in the control
of adiposity and body weight of animals on a high-fat diet.
DISCUSSION
The present study demonstrates that genetic and pharma-
cological blockade of the cannabinoid CB1 receptor in-
creases mitochondrial biogenesis in white adipocytes.
Treatment of adipocytes with SR141716, a selective antag-
onist of CB1 receptors (14,15,27), increases mitochondrial
biogenesis genes, including PGC-1 and Tfam. This possi-
bly implies that SR141716 is antagonizing an endocannabi-
noid tone present in cultured fat cells. It has been recently
reported by us and others (28,29) that rodent and human
adipocytes produce and release endocannabinoids, includ-
ing 2-arachidonoylglycerol, anandamide, and other canna-
bimimetic compounds. Thus, our results suggest that
SR141716 increases mitochondrial biogenesis by antago-
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DIABETES, VOL. 57, AUGUST 2008 2033nizing the endocannabinoids produced in cell culture. In
turn, this strongly implies that the CB1 receptor agonists
might downregulate the eNOS-dependent mitochondrial
biogenesis in white adipocytes. Consistently, cannabi-
noids, including (9)-tetrahydrocannabinol, inhibit the re-
spiratory enzyme system in brain, liver, skeletal muscle,
and heart (30) and, consequently, reduce the rates of
oxygen consumption in rodents (31,32).
We have recently found that eNOS-dependent NO pro-
duction induces mitochondrial biogenesis in different cell
types, including white adipocytes, by cGMP-dependent
pathways and that the newly synthesized mitochondria are
functionally active, ensuing high oxygen consumption and
ATP production (5,6,33). This suggests that the SR141716-
dependent increase in eNOS expression is mechanistically
linked to the mitochondrial biogenesis induced by the CB1
receptor blockade. This was conﬁrmed by the observation
that gene silencing of eNOS by RNAi markedly impairs the
SR141716 stimulatory effects on mitochondrial biogenesis
and function in cultured adipose cells.
We observed that genetic CB1 receptor blockade in vivo
increases eNOS expression and mitochondrial biogenesis
both in whole WAT and isolated mature white adipocytes,
and this is accompanied by prevention of high-fat diet–
induced fat accumulation. Most importantly, the pharma-
cological CB1 receptor blockade fully counteracts the
downregulation of eNOS-dependent mitochondrial biogen-
esis due to a high-fat diet in mice. This might indicate a
novel, previously unrecognized mechanism of action of
SR141716 as an antiobesity drug. Not only would it tran-
siently suppress food intake (34,35) and reduce lipogene-
sis (12), but it also would increase the oxidative
metabolism in white adipocytes by counteracting the
inhibitory effects of endocannabinoids, whose levels are
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Thus, we propose that the overactivity of endocannabi-
noids might contribute to downregulate mitochondrial
biogenesis in white adipocytes of obese mice and that the
blockade of adipose CB1 receptor might revert this pro-
cess, thus preventing the high-fat diet–induced increase in
adiposity and body weight gain.
There is an open question regarding the mechanisms
that link CB1 receptor blockade to the eNOS expression.
Furthermore, it remains to be clariﬁed how the recovery
of mitochondrial biogenesis and function in WAT could
counteract the development of obesity. We found that
SR141716 enhances AMPK activity in cultured white adi-
pocytes and that the WAT AMPK activity, which is reduced
by a high-fat diet, is normalized in WAT from high-fat
diet–fed CB1
/ mice to the levels measured in wild-type
standard-diet–fed mice. Since AMPK is known to enhance
NO production by activating eNOS (25), the AMPK cas-
cade might operate upstream of the NO generating system,
possibly contributing to the CB1 blockade–mediated mi-
tochondrial biogenesis. Accordingly, induction of AMPK
activity has been found to increase mitochondrial content
in adipocytes (36,37). Thus, the enhanced -oxidation of
free fatty acids elicited by AMPK activation (36,38) and by
eNOS-dependent mitochondrial biogenesis (39) might
functionally link SR141716 treatment to its antiobesity
effects.
The mechanisms that link eNOS-derived NO to the gene
expression machinery involved in mitochondrial biogene-
sis also remain to be elucidated. Studies of eNOS
/ mice
have demonstrated an obligatory role of eNOS in mito-
chondrial biogenesis (5,6). Noticeably, eNOS, NO, and its
intracellular messenger cGMP are located in both the
cytoplasm and the nucleus, and several transcription fac-
tors possess heme moieties that can bind NO (6), but
further investigation is needed to understand whether
eNOS-mediated responses involve the nuclear NO/cGMP.
It is now widely accepted that obesity is causally linked
to a chronic, low-grade inﬂammation of visceral adipose
tissue, characterized by inﬁltrating macrophages, abnor-
mal cytokine production, and activation of a network of
inﬂammatory signaling pathways, including tumor necro-
sis factor- and inducible NOS (iNOS) (40,41). It has been
observed that upregulation of iNOS (which is induced in
inﬂammatory conditions) often correlates with a down-
regulation of eNOS (16). Corroborating this, tumor necro-
sis factor- increases iNOS expression in different cells
and tissues, including fat (42) and inhibits eNOS expres-
sion, mitochondrial function, and energy production in
WAT (16). Interestingly, SR141716 has been shown to
reduce plasma tumor necrosis factor- levels in inﬂamma-
tory conditions (43). Thus, we can speculate that the
anti-inﬂammatory effects of SR141716 could help counter-
acting the increase of iNOS expression and the reduction
of eNOS expression and mitochondrial biogenesis in high-
fat diet–induced obesity.
Endogenous cannabinoids and CB1 agonists promote
vasodilation and decrease blood pressure, particularly in
rodent models of hypertension (44,45). A variety of puta-
tive mechanisms could explain these effects, including the
increased production of vasodilator NO in vessels. Al-
though we have not analyzed the possible effects of
SR141716 on eNOS expression in the vasculature, a recent
analysis of the impact of rimonabant on blood pressure in
the pooled population from four large trials with similar
design (the Rimonabant-In-Obesity Program) demon-
strates that there is no effect of rimonabant on blood
pressure beyond the modest reduction mediated by weight
loss (46).
In conclusion, our results demonstrate that mitochon-
drial biogenesis and function, which are impaired by a
high-fat diet, are restored to normal levels in white adipo-
cytes by the CB1 receptor antagonist SR141716, and this is
accompanied by prevention of adiposity and body weight
increase in high-fat–fed obese mice. In view of the present
ﬁndings, targeting eNOS expression and mitochondrial
biogenesis might offer therapeutic gains and simplify the
drug approach to clinical situations as complex as obesity
and related disorders.
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